TheraRadar
Clinical-Stage Companies / Green Cross Corporation

Green Cross Corporation

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 7/5/2022

45
Total Trials
20
Phase 3
14
Phase 2
1
Recruiting
457
Score

Pipeline by Phase

Phase 3
20
Phase 2
14
Phase 1
15

Therapeutic Focus

Influenza Influenza, Human Hunter Syndrome Kawasaki Disease Bacterial Infections

Clinical Trials (45)

NCT03920540 Phase 3 COMPLETED

A Study of GC1111 in Hunter Syndrom Patients

Started: 3/9/2017

NCT02783482 Phase 3 COMPLETED

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Started: 10/1/2016

NCT03947138 Phase 3 COMPLETED

A Study of GC3107(BCG Vaccine) in Healthy Infants

Started: 8/6/2019

NCT03492710 Phase 3 WITHDRAWN

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

Started: 4/30/2019

NCT02917304 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older

Started: 10/10/2016

NCT02541253 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children

Started: 9/1/2015

NCT02063789 Phase 3 COMPLETED

An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Started: 6/1/2014

NCT01750814 Phase 3 COMPLETED

To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults

Started: 6/1/2013

NCT02352584 Phase 3 COMPLETED

A Multicenter, Double-blind, Parallel Phase III Study

Started: 10/1/2014

NCT01987011 Phase 3 COMPLETED

Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers

Started: 8/1/2013

NCT02361866 Phase 3 COMPLETED

To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults

Started: 5/1/2014

NCT01645189 Phase 3 COMPLETED

Safety and Efficacy of Hunterase

Started: 7/1/2012

NCT01696305 Phase 3 COMPLETED

Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After Thyroidectomy

Started: 12/1/2012

NCT01406470 Phase 3 COMPLETED

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

Started: 9/1/2011

NCT01315496 Phase 3 TERMINATED

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

Started: 10/1/2009

NCT01535417 Phase 3 COMPLETED

Efficacy and Safety of Shinbaro Capsule

Started: 5/1/2009

NCT01201902 Phase 3 COMPLETED

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Started: 10/1/2009

NCT05422508 Phase 2 RECRUITING

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Started: 7/5/2022

NCT01624532 Phase 2 COMPLETED

A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109

Started: 7/14/2021

NCT04555148 Phase 2 COMPLETED

COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

Started: 9/19/2020

NCT03375502 Phase 2 COMPLETED

A Study of MG1111 in Healthy Children

Started: 11/26/2016

NCT04175522 Phase 2 COMPLETED

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

Started: 11/20/2019

NCT03657719 Phase 2 COMPLETED

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects

Started: 10/1/2018

NCT02304315 Phase 2 COMPLETED

A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients

Started: 2/1/2015

NCT01402713 Phase 2 COMPLETED

To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children

Started: 8/1/2011

NCT01328938 Phase 2 COMPLETED

GCPGC in Chemotherapy-induced Neutropenia

Started: 10/1/2010

NCT03454620 Phase 1 COMPLETED

A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

Started: 4/2/2018

NCT03855696 Phase 1 COMPLETED

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

Started: 1/21/2019

NCT03357263 Phase 1 COMPLETED

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

Started: 11/20/2017

NCT02569372 Phase 1 COMPLETED

A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients

Started: 11/9/2015

NCT02367638 Phase 1 COMPLETED

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

Started: 3/1/2015

NCT01653444 Phase 1 COMPLETED

Evaluate the Safety and Exploratory Efficacy of GC1119

Started: 11/1/2012

NCT01809912 Phase 1 TERMINATED

Safety Study of MG1102 in Patients With Solid Tumors

Started: 11/1/2010

NCT01954238 Phase 1 COMPLETED

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

Started: 8/1/2013

NCT02249221 Phase 1 COMPLETED

Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

Started: 10/1/2014

NCT01389466 Phase 1 COMPLETED

Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers

Started: 2/1/2010

NCT02121782 Phase 1 COMPLETED

A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)

Started: 5/1/2014

NCT01606163 Phase 1 COMPLETED

Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection

Started: 8/1/2012

NCT01651234 Phase 1 COMPLETED

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers

Started: 3/1/2012

NCT01363934 Phase 1 COMPLETED

To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin

Started: 6/1/2011

NCT01301898 Phase 1 COMPLETED

To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients

Started: 5/1/2010

NCT04003844 Phase 4 COMPLETED

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

Started: 2/1/2019

NCT02067117 Phase 4 COMPLETED

Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.

Started: 10/1/2010

NCT01604239 Phase 4 COMPLETED

To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis

Started: 5/1/2012

NCT01524939 Phase 4 COMPLETED

Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease

Started: 1/1/2012

Drug Candidates

MG1111 (BARICELA) VARIVAX Suduvax GC1109 or Placebo of GC1109 GC5107 GC3107 Intradermal BCG SSI inj. irinotecan FOLFIRI MG1113
Activity Status: Inactive
Last Trial Started: 7/5/2022
Last Trial Ended: 12/19/2022
Trials (12 months): 0
Completed Trials: 41
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.